1. Home
  2. HURA vs MX Comparison

HURA vs MX Comparison

Compare HURA & MX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HURA
  • MX
  • Stock Information
  • Founded
  • HURA 2009
  • MX 2003
  • Country
  • HURA United States
  • MX South Korea
  • Employees
  • HURA N/A
  • MX N/A
  • Industry
  • HURA
  • MX Semiconductors
  • Sector
  • HURA
  • MX Technology
  • Exchange
  • HURA Nasdaq
  • MX Nasdaq
  • Market Cap
  • HURA 126.1M
  • MX 103.8M
  • IPO Year
  • HURA N/A
  • MX N/A
  • Fundamental
  • Price
  • HURA $2.43
  • MX $3.24
  • Analyst Decision
  • HURA Strong Buy
  • MX Strong Buy
  • Analyst Count
  • HURA 2
  • MX 2
  • Target Price
  • HURA $11.50
  • MX $5.75
  • AVG Volume (30 Days)
  • HURA 237.9K
  • MX 261.0K
  • Earning Date
  • HURA 11-13-2025
  • MX 10-29-2025
  • Dividend Yield
  • HURA N/A
  • MX N/A
  • EPS Growth
  • HURA N/A
  • MX N/A
  • EPS
  • HURA N/A
  • MX N/A
  • Revenue
  • HURA N/A
  • MX $234,243,000.00
  • Revenue This Year
  • HURA N/A
  • MX N/A
  • Revenue Next Year
  • HURA N/A
  • MX $7.05
  • P/E Ratio
  • HURA N/A
  • MX N/A
  • Revenue Growth
  • HURA N/A
  • MX 16.02
  • 52 Week Low
  • HURA $1.80
  • MX $2.51
  • 52 Week High
  • HURA $8.40
  • MX $5.16
  • Technical
  • Relative Strength Index (RSI)
  • HURA 43.35
  • MX 57.76
  • Support Level
  • HURA $2.35
  • MX $2.89
  • Resistance Level
  • HURA $2.64
  • MX $3.16
  • Average True Range (ATR)
  • HURA 0.17
  • MX 0.09
  • MACD
  • HURA -0.03
  • MX 0.05
  • Stochastic Oscillator
  • HURA 22.03
  • MX 95.89

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

About MX Magnachip Semiconductor Corporation

MagnaChip Semiconductor Corp designs and manufactures analog and mixed-signal semiconductor platform solutions for communications, Internet of Things applications, consumer, industrial and automotive applications. The company's product portfolio consists of large display solutions, mobile display solutions, sensor solutions, LED solutions, mobile solutions, and power conversions. The company operates in two segments namely, Transitional Fab 3 foundry services and Standard products business. The company operates in Korea, Asia Pacific (other than Korea), United States and Europe.

Share on Social Networks: